PharmChem, Inc.
PCHM · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.59 | -0.78 | -0.30 | 0.03 |
| FCF Yield | 2.67% | 2.79% | 1.11% | 2.97% |
| EV / EBITDA | 34.18 | 31.37 | 29.39 | 21.72 |
| Quality | ||||
| ROIC | 10.63% | 13.08% | 10.52% | 19.76% |
| Gross Margin | 64.22% | 63.87% | 64.60% | 65.17% |
| Cash Conversion Ratio | 1.47 | 1.33 | 0.50 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.35% | 1.40% | 0.32% | -0.77% |
| Free Cash Flow Growth | -1.52% | 126.78% | -65.35% | 118.99% |
| Safety | ||||
| Net Debt / EBITDA | -5.37 | -3.93 | -5.37 | -3.30 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.42 | 2.41 | 1.85 | 3.05 |
| Cash Conversion Cycle | 21.06 | 49.22 | 53.88 | 39.78 |